Hypopharyngeal cancer medical therapy
|
Hypopharyngeal cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Hypopharyngeal cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Hypopharyngeal cancer medical therapy |
|
Risk calculators and risk factors for Hypopharyngeal cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gertrude Djouka, M.D.[2], Faizan Sheraz, M.D. [3]
Overview
The medical therapy with the combination of the radiotherapy has been used compared to surgical therapy for the treatment of hypopharyngeal cancer.The optimal therapy for hypopharyngeal cancer depends on the stage at the time of the diagnosis. The combined treatment helps with organ preservation. Swallowing, speech and laryngeal preservation are important to consider during the treatment.
Medical Therapy
The medical therapy with radiotherapy has been used compared to surgical therapy for the treatment of hypopharyngeal cancer due to organ preservation.[1] The optimal therapy for hypopharyngeal cancer depends on the stage at the time of diagnosis. The following factors are important to consider:[2]
Radiation Therapy
- Radiation therapy is used for early and localized lesions.
- Radiation therapy is used as a single modality treatment in early lesions.
- Laser surgery is gradually replacing radiotherapy for early lesions as the outcome of both are similar while the laser therapy requires a shorter in-patient period following the procedure.
- Thyroid hormone is recommended before and after radiation therapy.
References
- ↑ Lefebvre JL, Ang KK (April 2009). "Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary". Int. J. Radiat. Oncol. Biol. Phys. 73 (5): 1293–303. doi:10.1016/j.ijrobp.2008.10.047. PMID 19306746.
- ↑ Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T (July 1996). "Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group". J. Natl. Cancer Inst. 88 (13): 890–9. PMID 8656441.